Articles related to STATINS/CHOLESTEROL MANAGEMENT

The USPSTF comes to the conclusion that statin use has at least a moderate net benefit for adults aged 40 to 75 who have no prior history of CVD, at least one CVD risk factor, and an estimated 10-year CVD event risk of 10% or greater. There is at least a marginal net benefit from using statins to prevent CVD events and all-cause mortality in adults aged 40 to 75 who have no prior history of CVD, at least one of these risk factors, and an estimated 10-year CVD event risk of 7.5% to less than 10%. Still, is the evidence enough?

A conversation with Ann Marie Navar, MD, PhD, associate professor of cardiology at UT Southwestern in Dallas, Texas and associate editor of JAMA Cardiology, who discusses common statin-related myths, the safety of statin therapy, and reliable sources of information for patients.

In a look “Beyond the Guidelines,” a preventive cardiologist and a general internist discuss their approach in the case of a 57-year-old woman with high cholesterol and a family history of heart disease.

A meta-analysis published in JAMA Internal Medicine has concluded that the link between statin-induced LDL lowering and reduction of CV outcomes may not be as robust as previously assumed. According to the researchers, the absolute risk reduction associated with statin use for all-cause mortality was 0.8% (95% CI, 0.4-1.2), whereas for MI it was 1.3% (95% CI, 0.9-1.7) and for stroke it was 0.4% (95% CI, 0.2-0.6). Absolute risk reduction figures were slightly higher for secondary prevention than for primary prevention.

Publication: JAMA Internal MedicineDesign: Retrospective cohort study of more than 83,000 propensity-scored matched pairs over a 12-year period.Results: Diabetes progression was significantly greater among diabetes patients using statins vs. those not using statins.